Overview of the clinical application of regenerative medicine products in Japan

Health Policy

Volumn 88, Issue 1, 2008, Pages 62-72

  Tsubouchi, Mina ^a   Matsui, Shigeyuki ^a   Banno, Yoshiro ^b   Kurokawa, Kiyoshi ^b   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b 11 Toyo Kaiji Bldg   (Japan)

Author keywords

Biologics; Interview survey; Regenerative medicine; Regulatory guideline

Indexed keywords

ARTICLE; EUROPEAN UNION; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; JAPAN; PRACTICE GUIDELINE; QUALITY CONTROL; QUESTIONNAIRE; REGENERATIVE MEDICINE; SAFETY; SEMI STRUCTURED INTERVIEW; UNITED STATES;

CLINICAL PROTOCOLS; EUROPEAN UNION; HUMANS; INTERVIEWS AS TOPIC; JAPAN; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; REGENERATIVE MEDICINE; UNITED STATES;

EID: 50149093837     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2008.02.011     Document Type: Article

References (13)

1. Wilan K.H., Scott C.T., and Herrera S. Chasing a cellular fountain of youth. Nature Biotechnology 23 (2005) 807-815
2. Browne J.E., and Branch T.P. Surgical alternatives for treatment of articular cartilage lesions. The Journal of the American Academy of Orthopaedic Surgeons 8 (2000) 180-189
3. Moustafa M., Simpson C., Glover M., Dawson R.A., Tesfaye S., Creagh F.M., et al. A new autologous keratinocyte dressing treatment for non-healing diabetic neuropathic foot ulcers. Diabetic Medicine 21 (2004) 786-789
4. Japan Patent Office. The trend of application technology: the post-genome technology; 2002 [in Japanese].
5. Ministry of Health, Labour and Welfare, Japan. Notice for quality and safety of cellular and tissue-based pharmaceuticals and devices (notification no. 906, Drug and Food Bureau of the MHLW); 1999 [in Japanese].
6. Ministry of Health, Labour and Welfare, Japan. Notice for quality and safety of pharmaceuticals that use human- or animal-derived materials (notification no. 1314, Drug and Food Bureau of the MHLW); 2000 [in Japanese].
7. Ministry of Health, Labour and Welfare, Japan. Guidelines for clinical research utilizing human somatic stem cells; 2006 [in Japanese].
8. Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration. Guidance for reviewers: instructions and template for chemistry, manufacturing, and control (CMC) reviewers of human somatic cell therapy investigational new drug applications (INDs); 2003.
9. Commission of the European Communities. Regulation of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004; 2005.
10. Laeeque H., Boon H., Kachan N., Cohen J.C., and D'Cruz J. The Canadian natural health products (NHP) regulations: industry perceptions and compliance factors. BMC Health Services Research (2006) 6
11. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Preclinical safety evaluation of biotechnology-derived pharmaceuticals, S6; 2000.
12. European Parliament and Council. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use; 2005.
13. Tanaka K. PMDA and near-future regenerative medicine. Saiseiiryou 5 (2006) 206-215 [in Japanese]